[HT942526TERPCTA] DoW Toxic Exposures Clinical Trial Award

Description

Titolo: DoW Toxic Exposures Clinical Trial Award Numero dell'opportunità: HT942526TERPCTA Stato: aperto (posted) Tipo di opportunità: Discretionary Ente: Defense Health Agency Contracting Activity - DHACA — Department of Defense Tipo di finanziamento: Grant Categoria: Science and Technology and other Research and Development Programma (ALN): 12.420 Military Medical Research and Development Pubblicato il: 2026-05-21 Scadenza per le domande: 2026-11-19 Finanziamento totale stimato: 4,500,000 USD Numero di finanziamenti attesi: 1 Cofinanziamento richiesto: no Chi può fare domanda: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility" Descrizione: Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO) . One Principal Investigator (PI) is identified as the initiating PI, and an additional PI may be identified as a Partnering PI. If recommended for funding, each PI will be named on separate awards. The intent is to support interdisciplinary partnerships, such as those between clinicians and research scientists, that will accelerate the movement of promising interventions/​knowledge products into clinical applications. Partnering should significantly advance the research beyond what would be possible through independent efforts. https://cdmrp.health.mil/pubs/press/2026/terppreann Contatto: [email protected]

Sectors

Source

Source: grants.gov